Faisal Fa'ak

发表

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

J. Wargo, P. Sharma, A. Lazar, 2022, Cancer cell.

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

M. Suarez‐Almazor, C. Yee, S. Tummala, 2019, Journal of Immunotherapy for Cancer.

A Case Report of Atezolizumab Induced Tumor Lysis Syndrome

Faisal Fa'ak, Diego Vanegas, K. Osei, 2019, The American journal of case reports.

Cardiomyocyte-specific conditional knockout of the histone chaperone HIRA in mice results in hypertrophy, sarcolemmal damage and focal replacement fibrosis

R. Schwartz, B. Soibam, B. McConnell, 2016, Disease Models & Mechanisms.

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation

M. Suarez‐Almazor, M. Konopleva, G. Garcia-Manero, 2021, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade

P. Hwu, U. Marathi, Leila J. Williams, 2022, The Journal of clinical investigation.

Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors

A. Diab, Faisal Fa'ak, 2021 .

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

P. Hwu, C. Hudgens, M. Tetzlaff, 2017, Journal of Immunotherapy for Cancer.

Direct Measurement of Left Atrial Pressure during Routine Transradial Catheterization.

George A Younis, Faisal Fa'ak, B. Shabaneh, 2016, Texas Heart Institute journal.

Mesp1 Marked Cardiac Progenitor Cells Repair Infarcted Mouse Hearts

P. Gunaratne, R. Schwartz, A. Cooney, 2013, Scientific Reports.

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

K. Rajapakshe, C. Coarfa, M. Hurwitz, 2020, Nature Communications.

Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic

J. Kucharczyk, S. Adams, M. Kwa, 2022, The oncologist.

Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors.

M. Suarez‐Almazor, M. Lopez‐Olivo, C. Rojas-Hernandez, 2020, Blood advances.

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

M. Suarez‐Almazor, I. Osman, J. Sparks, 2023, Journal for ImmunoTherapy of Cancer.

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Douglas B. Johnson, I. Osman, G. Long, 2023, Journal of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma

Douglas B. Johnson, I. Osman, G. Long, 2023, JAMA network open.